Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
Robert L. Ferris(University of Pittsburgh), Dan P. Zandberg(University of Pittsburgh Medical Center), Heath D. Skinner(University of Pittsburgh), William E. Gooding(UPMC Hillman Cancer Center), Moon J. Fenton(University of Tennessee Health Science Center), Housaiyin Li(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(City University of New York), Shaum Sridharan(University of Pittsburgh), Simion I. Chiosea(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Zahra Kelly(University of Pittsburgh Medical Center), Mark Kubik(University of Pittsburgh), Lazar Vujanović(UPMC Hillman Cancer Center)
Cited by 17
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688